

2020 - 1

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia

Robak Tadeusz¹², Kazmierczak Maciej³, Jarque Isidro⁴⁵, Musteață Vasile⁶, Trelinski Jacek¹², Cooper Nichola⁷, Kiessling Peter C.⁸, Massow Ute⁸, Woltering Franz⁸, Snipes Rose G.⁹, Ke Juan¹⁰, Langdon Grant¹¹, Bussel James Bruce¹², Jolles Stephen¹³

¹ Medical University of Lodz,

² Copernicus Memorial Hospital, Lodz,

³ Poznan University of Medical Sciences,

⁴ La Fe University and Polytechnic Hospital, Valencia,

⁵ Instituto de Salud Carlos III,

⁶ Institute of Oncology,

⁷ Imperial College Healthcare National Health Service Trust, London,

⁸ Union Chimique Belge (UCB) Pharma, Monheim-am-Rhein,

⁹ UCB Pharma, Raleigh,

¹⁰ UCB Pharma, Slough,

¹¹ PTx Solutions Ltd., London,

¹² Weill Cornell Medicine, New York,

¹³ University Hospital of Wales, Cardiff

Blood Advances

Nr. 4(17) / 2020 / ISSN 2473-9537

Disponibil online 15 March, 2021. Descarcări-0. Vizualizări-475



Copyright © 2011-2024 Instrumentul Bibliometric Național.

Institutul de Dezvoltare a Societății Informaționale.

Actualizat: 23.05.2024, accesat: 23.05.2024

Disponibil: <https://ibn.idsi.md>

